Plicamycin

CHEMBL1237054 Phase 4 Đã phê duyệt Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
1085.1 g/mol
LogP
0.6
Phase
4

Plicamycin (mithramycin) is an antineoplastic antibiotic produced by Streptomyces plicatus that intercalates into DNA and inhibits RNA synthesis by binding to the DNA double helix in a GC-rich region, blocking the action of RNA polymerase. It was used in the treatment of testicular cancer and hypercalcemia of malignancy, and has shown activity in breast cancer and lung cancer, though its use is limited by significant toxicity.

Khối lượng phân tử

1085,1000 g/mol

LogP

0,60

TPSA

358,00 Ų

Lipinski RO5

Không đạt

Lĩnh vực điều trị

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cấu trúc 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CO[C@H](C(=O)[C@@H](O)[C@@H](C)O)[C@@H]1Cc2cc3cc(O[C@H]4C[C@@H](O[C@@H]5C[C@@H](O)[C@H](O)[C@@H](C)O5)[C@H](O)[C@@H](C)O4)c(C)c(O)c3c(O)c2C(=O)[C@H]1O[C@H]1C[C@@H](O[C@@H]2C[C@@H](O)[C@@H](O[C@@H]3C[C@](C)(O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@H](O)[C@@H](C)O1

InChI

InChI=1S/C52H76O24/c1-18-30(72-35-15-31(43(59)21(4)68-35)73-33-13-28(54)42(58)20(3)67-33)12-26-10-25-11-27(49(66-9)47(63)41(57)19(2)53)50(46(62)39(25)45(61)38(26)40(18)56)75-36-16-32(44(60)22(5)69-36)74-34-14-29(55)48(23(6)70-34)76-37-17-52(8,65)51(64)24(7)71-37/h10,12,19-24,27-29,31-37,41-44,48-51,53-61,64-65H,11,13-17H2,1-9H3/t19-,20-,21-,22-,23-,24-,27+,28-,29-,31-,32-,33-,34-,35+,36+,37-,41+,42-,43-,44-,48+,49+,50+,51-,52+/m1/s1

Molecular Formula

C52H76O24

HBD / HBA

11 / 24

Liên kết có thể quay

15

Nguyên tử nặng

76

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

Plicamycin (mithramycin) is an antineoplastic antibiotic produced by Streptomyces plicatus that intercalates into DNA and inhibits RNA synthesis by binding to the DNA double helix in a GC-rich region, blocking the action of RNA polymerase. It was used in the treatment of testicular cancer and hypercalcemia of malignancy, and has shown activity in breast cancer and lung cancer, though its use is limited by significant toxicity.

Yes, Plicamycin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1237054. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 163659. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.